Support and Innovation for Oncology Drug Development

Sponsored by: CMIC Group

Our specialized oncology team, with extensive experience and an established network of KOLs, will support your project with strategic development planning, regulatory interaction, clinical studies and post-marketing promotion for companies entering the field of oncology. Schedule a virtual meeting with us today!

Look Deeper With Signatera: Personalized, tumor-informed test for actionable intelligence

Sponsored by: Natera

Featured Signatera ASCO Presentation: Dr. Noelia Tarazona will be presenting a new study evaluating the validity of Signatera ctDNA assay to detect molecular residual disease (MRD) in CRC patients who are at high risk of recurrence, during and after adjuvant chemotherapy. Serial ctDNA analysis detected MRD up to 16.6 months before radiologic imaging. Click here to dive deeper.

Not an official event of the 2020 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or the Conquer Cancer® The ASCO Foundation.